The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines

Vaccine
Christina von HunolsteinRoberto Nisini

Abstract

Synthetic oligodeoxynucleotides containing CpG immunostimulatory sequences (ISS) have been shown to act as potent adjuvants of type 1 immune responses when co-administered with protein or peptide vaccines. We have recently shown that ISS can increase the anti-polysaccharide (CHO) and anti-tetanus toxoid (TT) or anti-diphtheria (CRM) toxoid antibody levels if used as adjuvant of anti-Haemophilus influenzae type b (Hib) CHO vaccine conjugated with TT or CRM. The analysis of anti-TT and anti-CRM IgG subclasses showed a significant increase in IgG2a, IgG2b and/or IgG3 in the presence of ISS. Anti-TT and anti-CRM antibodies were shown to neutralize the activity of both the tetanus and diphtheria toxin in vivo or in vitro tests respectively. These data show that ISS have the potential to increase host antibody response against both the CHO and the protein component of a conjugated vaccine, and encourage the investigation to identify strategies of vaccination with schedules aimed at the valuation of protein carriers as protective immunogens.

References

May 1, 1992·Immunology Today·N S Greenspan, L J Cooper
Jan 11, 1990·Annual Review of Immunology·F D FinkelmanW E Paul
Jan 1, 1993·Vaccine·R K GuptaC K Gupta
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·D M KlinmanA M Krieg
Feb 1, 1996·Trends in Microbiology·A M Krieg
Jul 1, 1997·The Journal of Clinical Investigation·D A SchwartzA M Krieg
Dec 31, 1997·The Journal of Experimental Medicine·R S ChuC V Harding
Feb 17, 1998·European Journal of Immunology·G B LipfordH Wagner
Jul 23, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H Shams, I Heron
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·C L Brazolot MillanH L Davis
Mar 17, 1999·Vaccine·D M KlinmanJ Conover
Oct 3, 1999·Vaccine·M J McCluskie, H L Davis
Jul 19, 2000·Current Opinion in Immunology·V E Schijns
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·N S YewS H Cheng

❮ Previous
Next ❯

Citations

Dec 14, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Manish DiwanJohn Samuel
Jul 20, 2002·Vaccine·Yoshitsugu KojimaKenji Okuda
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
Nov 5, 2002·Clinical and Diagnostic Laboratory Immunology·Bruce PanilaitisJuliet Fuhrman
May 23, 2003·Infection and Immunity·Yu-Chi HsiehChi-Ming Liang
Jul 12, 2007·Seminars in Immunopathology·Chun-Ming Huang
Jul 6, 2004·Immunological Reviews·Dennis M KlinmanDaniela Verthelyi
Apr 22, 2011·Expert Review of Vaccines·Christian BodeDennis M Klinman
Jul 5, 2006·International Reviews of Immunology·Dennis M Klinman
Sep 21, 2005·Critical Reviews in Microbiology·Chi-Jen LeeXin-Xing Gu
Aug 30, 2013·Clinical and Vaccine Immunology : CVI·Stefan FernandezRobert G Ulrich
Dec 6, 2002·Journal of Medical Microbiology·Lanfranco FattoriniGraziella Orefici
May 3, 2021·The FEBS Journal·Marko AnderluhSandra J van Vliet
Sep 11, 2021·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Waleed H Mahallawi, Talal M Aljeraisi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.